HBV
HBV inhibitors are compounds designed to target and inhibit various stages of the Hepatitis B virus (HBV) lifecycle. These inhibitors can interfere with viral replication, assembly, or release, thereby reducing the viral load and helping to manage chronic HBV infections. Research into HBV inhibitors is crucial for developing effective antiviral therapies to prevent liver disease and cancer associated with HBV. At CymitQuimica, we offer a range of HBV inhibitors to support your research in virology, antiviral drug development, and infectious disease management.
Read more
Inarigivir
CAS:475650-36-3
Inarigivir (ORI-9020) is a dinucleotide that can significantly reduce liver HBV DNA.
Formula:
C20H26N7O10PS
Purity:
98%
Color and Shape:
Solid
Molecular weight:
587.5
Ref: TM-T7365
| 25mg | 1,410.00 € | ||
| 50mg | 1,851.00 € | ||
| 100mg | 2,337.00 € |
Estimated delivery in United States, on Monday 3 Feb 2025
HBV-IN-34
CAS:2716906-45-3
HBV-IN-34 (compound 17i) is a potent inhibitor of HBsAg production, demonstrating remarkable in vitro anti-HBV …
Formula:
C21H19F2N7
Purity:
98%
Color and Shape:
Liquid
Molecular weight:
407.42
Ref: TM-T79469
| 25mg | 1,410.00 € | ||
| 50mg | 1,851.00 € | ||
| 100mg | 2,337.00 € |
Estimated delivery in United States, on Monday 3 Feb 2025
Tivicilovir
CAS:103024-93-7
Tivicilovir (AM188) is a hepatitis B virus inhibitor. tiviclovir is a guanine-related acyclic 2'-deoxyguanine analogue …
Formula:
C9H13N5O3
Purity:
98.87%
Color and Shape:
Liquid
Molecular weight:
239.23
Ref: TM-T67813
| 1mg | 134.00 € | ||
| 5mg | 316.00 € | ||
| 10mg | 475.00 € | ||
| 25mg | 769.00 € | ||
| 50mg | 1,068.00 € | ||
| 100mg | 1,448.00 € | ||
| 500mg | 2,757.00 € | ||
| 1mL*10mM (DMSO) | 280.00 € |
Estimated delivery in United States, on Monday 3 Feb 2025
Lagociclovir
CAS:92562-88-4
Lagociclovir (MIV-210), a nucleoside analogue antiviral, treats HBV by inhibiting its replication in liver cancer …
Formula:
C10H12FN5O3
Purity:
98.90% - 99%
Color and Shape:
Solid
Molecular weight:
269.23
Ref: TM-T15704
| 1mg | 289.00 € | ||
| 5mg | 706.00 € | ||
| 10mg | 989.00 € | ||
| 25mg | 1,466.00 € | ||
| 50mg | 1,978.00 € | ||
| 1mL*10mM (DMSO) | 679.00 € |
Estimated delivery in United States, on Monday 3 Feb 2025
Yhhu6669
CAS:2569526-80-1
Yhhu6669 is an anti-HBV agent that suppresses viral DNA and replication by promoting DNA-free capsid …
Formula:
C29H28ClFN6O3
Purity:
98%
Color and Shape:
Liquid
Molecular weight:
563.02
Ref: TM-T78756
| 25mg | 1,549.00 € | ||
| 50mg | 2,038.00 € | ||
| 100mg | 2,617.00 € |
Estimated delivery in United States, on Tuesday 18 Feb 2025
Linvencorvir
CAS:1808248-05-6
Linvencorvir is a hepatitis B virus (HBV) core protein variant modifier used to treat chronic …
Formula:
C29H35FN6O5S
Purity:
100% - 99.79%
Color and Shape:
Liquid
Molecular weight:
598.69
Ref: TM-T64221
| 1mg | 647.00 € | ||
| 5mg | 1,114.00 € | ||
| 10mg | 1,808.00 € | ||
| 25mg | 2,063.00 € | ||
| 50mg | 2,265.00 € | ||
| 100mg | 2,950.00 € | ||
| 1mL*10mM (DMSO) | 1,331.00 € |
Estimated delivery in United States, on Tuesday 18 Feb 2025
HBF-0259
CAS:957011-15-3
HBF-0259 is an inhibitors of hepatitis B virus surface antigen (HBsAg) secretion with an EC50 …
Formula:
C16H12Cl2FN5
Purity:
90% - 99.88%
Color and Shape:
Solid
Molecular weight:
364.2
Ref: TM-T27527
| 1mg | 38.00 € | ||
| 2mg | 50.00 € | ||
| 5mg | 82.00 € | ||
| 10mg | 128.00 € | ||
| 25mg | 210.00 € | ||
| 50mg | 308.00 € | ||
| 100mg | 441.00 € | ||
| 500mg | 888.00 € | ||
| 1mL*10mM (DMSO) | 93.00 € |
Estimated delivery in United States, on Tuesday 18 Feb 2025
Oxynitidine
CAS:548-31-2
Oxynitidine, an HBV inhibitor (ID50 = 30.8 µg/mL), effectively suppresses HBV DNA replication and may …
Formula:
C21H17NO5
Purity:
98%
Color and Shape:
Liquid
Molecular weight:
363.36
Ref: TM-T80649
| 5mg | To inquire | ||
| 50mg | To inquire |
Estimated delivery in United States, on Tuesday 18 Feb 2025
Tenofovir amibufenamide
CAS:1571076-26-0
Tenofovir amibufenamide (HS-10234), an oral antiviral, targets HBV for chronic hepatitis B treatment.
Formula:
C22H31N6O5P
Purity:
99.19% - 99.86%
Color and Shape:
Liquid
Molecular weight:
490.49
Ref: TM-T39043
| 1mg | 217.00 € | ||
| 5mg | 538.00 € | ||
| 10mg | 806.00 € | ||
| 25mg | 1,290.00 € | ||
| 50mg | 1,791.00 € | ||
| 100mg | 2,458.00 € |
Estimated delivery in United States, on Tuesday 18 Feb 2025
HBV-IN-41
CAS:1967002-25-0
HBV-IN-41 (compound 45) is a potent, orally active inhibitor of Hepatitis B Virus (HBV), exhibiting …
Formula:
C18H19ClFN5O3
Purity:
98%
Color and Shape:
Liquid
Molecular weight:
407.83
Ref: TM-T79767
| 5mg | To inquire | ||
| 50mg | To inquire |
Estimated delivery in United States, on Tuesday 18 Feb 2025
HBV-IN-38
CAS:1834483-86-1
HBV-IN-38 (Example 193), an HBV DNA inhibitor with an EC50 value of ≤100 nM, serves …
Formula:
C18H16F3N5O4S2
Purity:
98%
Color and Shape:
Liquid
Molecular weight:
487.48
Ref: TM-T79879
| 5mg | To inquire | ||
| 50mg | To inquire |
Estimated delivery in United States, on Tuesday 18 Feb 2025
Tobevibart
CAS:2645440-65-7
Tobevibart, an IgG1-lambda humanized monoclonal antibody targeting the hepatitis B virus (HBV) surface envelope protein, …
Purity:
98%
Color and Shape:
Liquid
Ref: TM-T80970
| 1mg | 182.00 € | ||
| 5mg | 450.00 € | ||
| 10mg | 645.00 € | ||
| 25mg | 1,007.00 € | ||
| 50mg | 1,389.00 € |
Estimated delivery in United States, on Tuesday 18 Feb 2025
IR415
CAS:452967-14-5
IR415 selectively interacts with Hepatitis B virus X protein (HBx, Kd = 2 nM) and …
Formula:
C13H14F2N4S
Purity:
99.05%
Color and Shape:
Solid
Molecular weight:
296.34
Ref: TM-T11669
| 2mg | 46.00 € | ||
| 5mg | 71.00 € | ||
| 10mg | 111.00 € | ||
| 25mg | 217.00 € | ||
| 50mg | 377.00 € | ||
| 100mg | 559.00 € | ||
| 1mL*10mM (DMSO) | 77.00 € |
Estimated delivery in United States, on Tuesday 18 Feb 2025
HBV-IN-48
CAS:2743466-04-6
HBV-IN-48, an HBV inhibitor, exhibits potent antiviral activity against HBV in HepDE19 cells, demonstrated by …
Formula:
C22H15F4N3O3
Color and Shape:
Liquid
Molecular weight:
445.37
Ref: TM-T200299
| 10mg | To inquire | ||
| 50mg | To inquire |
Estimated delivery in United States, on Monday 17 Mar 2025
